Clearpoint Neuro (CLPT) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenue of $7.9 million, a 32% year-over-year increase, with all segments contributing to growth and product revenue more than doubling to $4.9 million.

• Platform technology with over 10 years of commercial experience in precision MRI-guided and OR-based therapies, expanding via A.I., machine learning, and strategic partnerships.

• Over 85 neurosurgery and research centers use the platform, targeting 100+ by 2025, with a total addressable market exceeding $12B.

• Revenue growth driven by product sales to pharma partners, new product launches, and global expansion, with seven pharma partner programs now in FDA expedited pathways.

• Company commercialized the Prism Neuro Laser Therapy System and SmartFrame OR, both receiving FDA clearance.

Financial highlights

• Q2 2024 revenue reached $7.9 million, up from $6 million in Q2 2023; six-month revenue was $15.5 million, up 36% year-over-year.

• Gross margin improved to 63% in Q2 2024 from 53% in Q2 2023, with trailing twelve months at 60%.

• Net loss for Q2 2024 was $4.4 million, improved from $7.1 million in Q2 2023; net loss per share was $0.16.

• Cash and cash equivalents stood at $32.8 million as of June 30, 2024, up from $23.1 million at year-end 2023, bolstered by a $16.2 million public stock offering.

• Operational cash burn reduced by 47% year-over-year in Q2, and by 46% over the trailing 12 months.

Outlook and guidance

• Full-year 2024 revenue guidance raised to $30–$33 million, representing 25%–38% annual growth, with plans for global expansion to 100+ centers by 2025.

• Cash flow breakeven targeted by end of 2025, supported by disciplined spending and margin expansion.

• Revenue guidance reflects timing uncertainties in pharma services and milestone payments.

• Management expects current liquidity to cover at least twelve months of operations.